Kornimate/medical-research-clean huggingface dataset:
effect of acute treatment with n2o on inhibitory pain mechanisms in healthy subject

Conditions: Pain

Summary: the purpose of this study is to determine whether n2o (laughing gas) has an antinociceptive effects in healthy volunteers.

10 healthy volunteers will come twice to the pain medicine unit, at 1 visit they'll get n2o and in the second visit they'll get air as placebo, they won't know what they're getting. during the visit they'll get heat stimulus using qst and will have to report their pain using evas (scale from 0 to 100 when 0 is no pain and 100 is the worst pain imagine).

Eligibility criteria:
inclusion criteria: * 18-50 years old * women and men * healthy exclusion criteria: * smokers * medication use pregnant woman cardiovascular disease
biomarkers in tissue samples from patients who have undergone neck dissection for oral cancer

Conditions: Head and Neck Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at tissue samples in predicting oral cancer in patients who have undergone neck dissection for oral cancer.

objectives: * to test preliminary data from node-positive oral squamous cell carcinoma (oscc) signatures for their ability to predict lymph-positive primaries using a cohort of oscc tumors. * to perform lymph node prediction using sentinel lymph node-biopsied primaries. * to validate the preliminary data node-positive oscc signature and test its ability to predict nodal status. outline: patient tissue samples are screened using polymerase chain reaction (pcr) for human papilloma virus-specific primers. samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. samples also undergo microarray analysis to quantify expression levels for targeted genes. initial data analysis is performed using affymetrix® microarray suite 5.0 to quantify expression levels for targeted genes.

Eligibility criteria:
* have a primary tumor specimen banked by the american college of surgeons oncology group (acosog) as part of clinical trial acosog-z0360 \* all tumor specimens are squamous cell carcinomas of the tongue, floor of the mouth, or gingiva * all patients have undergone neck dissections \* pathologically confirmed nodal stage (negative or positive)

Keywords: stage i squamous cell carcinoma of the lip and oral cavity stage ii squamous cell carcinoma of the lip and oral cavity tongue cancer
refraining from closed reduction of dislocated distal radius fractures in the emergency department

Conditions: Wrist Fractures; Distal Radius Fractures; Closed Reduction of Fracture and Application of Plaster Cast; Wrist Injuries; Radius Fracture Distal

Summary: the investigators test the efficacy of closed reduction in displaced distal radial fractures in the emergency department.

in a multicenter cluster randomized trial the investigators aim to include 134 patients with displaced distal radial fractures awaiting surgery and randomize between closed reduction followed by plaster casting and plaster casting alone. primairy outcomes are pain in the days leading up to surgery and postoperative hand- and wrist function. secondary outcomes are length of stay in the emergency department, length of surgey, return to work and complications.

Eligibility criteria:
inclusion criteria: * displaced distal radial fracture eligible for surgery exclusion criteria: * iss traumascore \>16 * open fracture * multiple fractures in ipsilateral extremety * neurovascular damage * previous injury in the same wrist * inability to complete questionnaires
hypothyroidism treated with calcitonin

Conditions: Hypothyroidism

Summary: some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. we are testing whether giving calcitonin to such people will improve their quality of life.

it is known that a proportion of patients with hypothyroidism despite serum tsh levels being within the normal reference range, may continue to express symptoms of hypothyroidism. common symptoms include fatigue, muscle pain, weight gain, and mood changes. saravanan et al. reported in a large community-based survey that patients on levothyroxine even with a normal tsh showed significant impairment in psychological well-being compared with age- and sex-matched controls. these patients are challenging to manage and are often unhappy with they care. established treatment of hypothyroidism is levothyroxine. thyroid follicular cells synthesize and secrete thyroxine and triiodothyronine. however, even when people are receiving adequate levothyroxine replacement therapy, their quality of life may not improve. calcitonin (ct) is also produced by the thyroid gland, parafollicular cells. their levels are not tested in hypothyroidism because the exact role of calcitonin in human health and disease is not fully known. ct has long been thought to play an important role in bone and mineral homeostasis, particularly with respect to its ability to regulate calcium metabolism. ct has been found in fish, reptiles, birds, and mammals. salmon-derived ct is 50-100 times more potent than human ct. hence, salmon ct (sct) has been used for medicinal purposes. there is a need for further research in order to understand the nature of persisting symptoms in patients on t4 monotherapy despite a serum tsh within the reference range. calcitonin has been shown to alleviate pain in patients with bone or mineral disorders. to date, the use of calcitonin for relief of hypothyroid symptoms has not been studied.

Eligibility criteria:
inclusion criteria: * normal tsh on levothyroxine therapy exclusion criteria: 1. pregnant or 6 months post partum 2. current or previous thyroid cancer 3. congenital hypothyroidism 4. any tobacco use 5. prescribed proton pump inhibitors 6. prescribed steroids 7. taking armour thyroid, naturethroid, or any dessicated thyroid hormone 8. unstable medical conditions (ckd, cirrhosis etc) 9. pituitary disease
tas-102 combined with bevacizumab and tislelizumab third-line or above in the treatment of liver metastasis in colorectal cancer

Conditions: Immunotherapy; Colorectal Cancer

Summary: to evaluate the clinical efficacy and safety of tas-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.


Eligibility criteria:
inclusion criteria: * patients who provided informed consent and voluntarily enrolled * patients with liver metastasis of advanced colorectal adenocarcinoma with mss confirmed by pathology; * 18-75 years old; * measurable target lesions according to recist v1.1 assessment criteria; * progression after standard second-line treatment (irinotecan, oxaliplatin, or fluorouracil); * 0 \~ 2 points according to ecog quality of life score; * drugs can be taken orally * estimated survival ≥3 months; * women of childbearing age should comply with contraceptive measures if pregnancy test is negative; * ascites with no obvious symptoms and no clinical intervention; * adequate organ and bone marrow functions, ecg, blood, biochemical and other basic tests are not contraindications of chemotherapy; * adherence to scheduled visits, treatment plans, laboratory tests, and other study procedures willingness and ability. exclusion criteria: * previous application of tas-102; * pregnant or lactating women; * no contraception during the reproductive period; * patients known to have a history of allergy to any study drug, similar drug or excipient; * patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction; * patients with a history of thromboembolism, except those caused by picc; * patients with active infection; * patients with uncontrolled hypertension (systolic blood pressure ≥160 mmhg and diastolic blood pressure ≥90) mmhg); * patients with brain metastases with clinical symptoms or imaging evidence; * contraindications for treatment of other chronic diseases; * previous immunotherapy-related myocarditis, pneumonia, colitis, hepatitis, kidney inflammation and other conditions, the current ae is still ≥2; * according to the nci ctcae 5.0 assessment criteria, there are all types of existing cases due to previous treatment patients with grade ≥2 toxic reactions; * other conditions that the investigator determines are not suitable for inclusion in the study. * received any anti-tumor therapy and participated in other clinical studies within 4 weeks prior to enrollment.
molecular imaging visualization of tumor heterogeneity in non-small cell lung cancer

Conditions: NSCLC; PET/CT; Biopsy; Radiomics; Genomics; Whole-exome Sequencing

Summary: to assess the potential usefulness of radiogenomics for tumor driving genes heterogeneity in non-small cell lung cancer.

patients with advanced nsclc underwent 18f-fdg pet/ct and pet/ct-guided synchronous targeted biopsy of primary and distant metastatic tumors. the lifex package was used to extract pet and ct radiomic features from primary and metastatic lesions. the radiomic roi sites of primary and distant metastatic tumors were point-to-point corresponding to the pet/ ct-guided targeted biopsy sites. whole exon sequencing of primary and distant metastatic tumor samples obtained by pet/ct-guided targeted biopsy was used to get genomic data of primary and distant metastatic tumor. predictive radiogenomics models were established and validation.

Eligibility criteria:
criteria: inclusion criteria: * (i) adult patients (aged 18 years or order); * (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (mri), ct, tumor markers and pathology report); * (iii) patients who had scheduled both 18f-fdg pet/ct scans and pet/ct guided biopsy; * (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: * (i) patients with non-malignant lesions; * (ii) patients with pregnancy; * (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: nsclc, pet/ct, radiogenomics
magnolia: extension study of patients with non-infectious uveitis who participated in cls1001-301

Conditions: Uveitis; Uveitis, Posterior; Uveitis, Anterior; Uveitis, Intermediate; Panuveitis

Summary: this study is a non-interventional, observational extension of the parent study, cls1001-301 (nct02595398). the purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered cls-ta, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.

this is a non-interventional, observation extension study of up to 6 months for subjects completing the parent study, cls1001-301 (nct02595398). the parent study is a phase 3, multicenter study to assess the safety and efficacy of 4 mg of cls-ta administered via suprachoroidal injection compared to a sham procedure in the treatment of subjects with macular edema associated with non-infectious uveitis. the design of the extension study includes 4 clinic visits over a maximum of 24 weeks. subject eligibility will be established at visit 1 during the crossover day from the parent study to the extension study (day 0). follow-up visits will be conducted every 6 weeks up to 24 weeks (visit 4). at visit 4, subjects will have a final evaluation conducted 24 weeks following study entry (48 weeks from parent study randomization). this study was initiated prior to the completion of the parent study, therefore treatment assignment was masked prior to study entry.

Eligibility criteria:
inclusion criteria: * enrolled in the parent study, cls1001-301, through visit 8/month 6 * willing and able to provide written informed consent prior to any study procedures; willing to comply with the instructions and attend all scheduled study visits exclusion criteria: * received additional therapy for the treatment of uveitis or prohibited medication * require additional therapy for the treatment of uveitis or prohibited medication at the time of the crossover visit

Keywords: uveitis ume posterior uveitis anterior uveitis intermediate uveitis panuveitis non-infectious uveitis triamcinolone choroid choroidal injection suprachoroidal microneedle microinjection triamcinolone acetonide
serratus posterior superior intercostal plane block versus suprascapular nerve block and axillary nerve block for analgesia in shoulder arthroscopic surgery

Conditions: Serratus Posterior Superior Intercostal Plane Block; Suprascapular Nerve Block; Axillary Nerve Block; Analgesia; Shoulder Arthroscopic Surgery

Summary: this study aims to compare the serratus posterior superior intercostal plane block and suprascapular nerve block and axillary nerve block for analgesia in shoulder arthroscopic surgery.

controlling postoperative pain while minimizing opioid administration is particularly important because poor pain control is thought to be responsible for more than 60% of unplanned or prolonged hospitalizations. suprascapular nerve block (ssnb) has been proposed based on the anatomic fact that the suprascapular nerve innervates approximately 70% of the shoulder joint, capsule, subacromial space, acromioclavicular joint, and coracoacromial ligament, with the remaining 30% thought to be innervated by the lateral pectoral and axillary nerve. the combined ssnb and axillary nerve block (anb) was proposed as a safe alternative to interscalene brachial plexus block (isb) for providing anesthesia and postoperative analgesia for shoulder surgery. serratus posterior superior intercostal plane block (spsipb) was described as a novel technique in a case series study of cadavers and five patients.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * scheduled for open thoracotomy. exclusion criteria: * infection at the site of regional blocks. * allergy to any drug used in this study. * use of psychotropic and/or narcotic medications on a regular basis. * cognitive dysfunction. * cardiovascular disease. * pulmonary disease. * coagulation abnormalities. * anatomical abnormalities. * neuropathic pain. * body mass index \>40. * history of substance abuse. * previous surgery in the same shoulder.
home with tablo outcomes (home) registry

Conditions: End Stage Renal Disease

Summary: prospective, multicenter, single arm, post-market study to evaluate real world clinical outcomes in esrd patients receiving in-home dialysis on the tablo hemodialysis system.


Eligibility criteria:
inclusion criteria: * participant (patient and/or care partner) is at least 15 years of age and has provided informed consent and has signed a health insurance portability and accountability act of 1996 (hipaa) compliant authorization statement. * participant weighs ≥ 34kg. * participant has end stage renal disease (esrd) adequately treated by maintenance dialysis. * participant plans to start or has started home treatment (≤ 6 months) with the tablo hemodialysis system. * participant is willing and able to comply with the protocol requirements and perform all site required treatments and clinical evaluations. exclusion criteria: * participant and/or care partner is unable to read english or spanish. * participant has a home environment that is deemed inappropriate for home dialysis. * participant and/or care partner is unable to successfully complete the tablo training program * participant is pregnant or plans to become pregnant.

Keywords: tablo outset medical esrd home hemodialysis hhd eskd
validation of edema-invariant multi-shell high angular resolution diffusion imaging (mshardi)-based tractography with intra-operative cortical stimulation

Conditions: Brain Lesions

Summary: currently, standard-of-care tractography is based on information obtained from diffusion tensor imaging (dti). dti is a diffusion magnetic resonance imaging (dmri) technique that is routinely obtained on neurosurgical patients to assist in pre-operative planning. the primary objective of the proposed study is to determine the ability of mshardi-based tractography to discern fibers in edematous brain regions.


Eligibility criteria:
inclusion criteria: * brain lesions, including but not limited to tumors, epileptic foci, and vascular abnormalities, in or around eloquent brain regions (i.e., motor, language); * clinical need for pre-operative 'advanced imaging' (which includes conventional dti); * age between 18-80 years of age; * male or female gender. eloquent regions include: temporal and frontal lobes (speech/language); bilateral occipital lobes (vision); bilateral parietal lobes (sensation); and bilateral motor cortex (movement). exclusion criteria: * a contraindication for obtaining an mri scan (e.g. implanted devices, retrained foreign body) * pregnancy * absence of the capacity to make medical decisions or provide informed consent.

Keywords: eloquent cortex
a study to evaluate the efficacy and safety of hcp2102 in essential hypertension patients

Conditions: Hypertension

Summary: a multicenter, randomized, double-blind, phase iii study to evaluate the efficacy and safety of hcp2102 in patients with essential hypertension


Eligibility criteria:
inclusion criteria: 1. patients aged ≥ 19 years 2. patients who understands the process of clinical study and voluntarily signs a peer letter 3. visit 1: a person whose blood pressure measured in visit 1 corresponds to the following conditions * blood pressure medication taken patients: 140mmhg ≤ sitsbp\<200mmhg, sitdbp\<120mmhg * blood pressure medication free patients: 160mmhg ≤ sitsbp\<200mmhg, sitdbp\<120mmhg 4. visit 2: 140mmhg ≤ sitsbp\<200mmhg, sitdbp\<120mmhg exclusion criteria: 1. difference between arms greater than 20 mmhg for mean sitsbp or 10 mmhg for mean sitdbp 2. orthostatic hypotension with symptoms within 3 months prior to visit 1 3. secondary hypertension patient or suspected to be 4. uncontrolled diabetes mellitus(hba1c \> 9%) or type i diabetes mellitus 5. active gout or hyperuricemia (uric acid ≥ 9mg/dl) 6. severe heart disease or severe neurovascular disease 7. severe or malignant retinopathy 8. clinically significant hematological finding 9. severe renal diseases (egfr\<30ml/min/1.73m2) 10. severe hepatopathy or active hepatopathy (ast or alt normal range ≥ 3 times) 11. hypokalemia or hyperkalemia(k\<3.5mmol/l or k ≥ 5.5mmol/l) 12. hyponatremia or hypernatremia(na\<135mmol/l or na ≥ 155mmol/l) 13. hypercalcemia(ca ≥ 10.5mg/dl) 14. history of malignancy tumor 15. history of autoimmune disease 16. history of alcohol or drug abuse 17. positive to pregnancy test, nursing mother, intention on pregnancy 18. considered by investigator as not appropriate to participate in the clinical study with other reason
postmenopausal women with vaginal microbiota

Conditions: HPV-Related Squamous Cell Carcinoma

Summary: since other genital infections enhance hiv susceptibility by inducing inflammation, the investigators study the relationship between the vaginal microbiota composition and the risk of hpv infection, cervical cytological abnormalities in postmenopausal women.

persistent infection with oncogenic human papillomavirus (hpv) is necessary but not sufficient for the development of cervical cancer. additional factors correlated with hpv persistence include immunodeficiency caused by hiv, smoking, use of oral contraceptives and, more recently reported, vaginal dysbiosis. in a state of dysbiosis, there is a marked reduction of lactobacillus and a high diversity of bacteria, with increased abundance of anaerobic bacterial species. owing to the decrease of estrogen level and cervical atrophy in postmenopausal women, cervical cytology is more prone to abnormal changes than in premenopausal women. clinically, cervical lesions in elderly women are easily neglected. therefore, cervical cancer in the elderly is usually found in advanced stage, with poor prognosis and more complications of treatment. based on this, the investigators are going to analyze the changes of microbiota in women with high-risk hpv and the cervical lesions in menopausal women. and the investigators hope to figure out the difference and change in microbiota to realize the tanning of cervical lesions.

Eligibility criteria:
inclusion criteria: * those are aged 20 to 75 years old, have had vaginal intercourse more than 3 years, and aren't in menstrual, pregnancy or puerperium period. exclusion criteria: * those have no vaginal intercourse, and can't cooperate the examiner. women who are hiv or hepatitis b/c positive, have autoimmune disorders and systemic disease (like diabetes mellitus, hormone treatment diseases, severe liver and kidney dysfunction), or have severe mental illness and malignant tumors are also excluded. at the same time, all the participants should meet the following requirements: no vagina douching within last 2 days, no vaginal intercourse within last 3 days, no systemic application of antifungal agents or antibiotics or pessaries within last 14 days of sampling.
investigation of functional parameters

Conditions: Grip; Pinch; Strength; Wrist; Dexterity

Summary: the goal of this cross-sectional study is to investigate the relationships between grip/pinch strengths, wrist flexion-extension strengths, wrist proprioception, manual dexterity, and bimanual coordination in healthy volunteers. the hypotheses are: h0: there is no relationship between grip/pinch strengths, wrist flexion-extension strengths, wrist proprioception, manual dexterity, and bimanual coordination. h1: there is a relationship between grip/pinch strengths, wrist flexion-extension strengths, wrist proprioception, manual dexterity, and bimanual coordination. within the scope of the study, the participants' active joint position sense (ajps) and flexion-extension strengths of the wrist were assessed using an isokinetic dynamometer. additionally, grip strength, key pinch, tip pinch, and palmar pinch strengths were evaluated using a dynamometer. the purdue pegboard test was used to assess manual dexterity and bimanual coordination.


Eligibility criteria:
inclusion criteria: after providing detailed information about the research, individuals who agreed to participate were included in the study. exclusion criteria: individuals who had undergone surgery or trauma in the upper extremity, had fractures or acute orthopedic injuries, had a history of neuromuscular diseases or congenital anomalies, had skin infections, or other conditions that could affect the assessment within the past 6 months were excluded from the study.
a phase 1/2 study to evaluate aln-khk in overweight to obese healthy volunteers and obese patients with t2dm

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: to evaluate the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of single ascending doses of aln-khk and to evaluate the safety, tolerability, efficacy, pk and pd of multiple doses of khk.


Eligibility criteria:
inclusion criteria: * stable euthyroid status (no known changes in thyroid function; stable hormone replacement for at least 4 months) at screening * part a: body mass index (bmi) ≥27 kg/m\^2 and ≤34.9 kg/m\^2 * part b: bmi ≥30 kg/m\^2 to ≤39.9 kg/m\^2, confirmed diagnosis of t2dm, and an hba1c ≥7.5% to \<10% * part b: confirmed t2dm diagnosis exclusion criteria: * parts a and b: has received an investigational agent within the last 30 days * part a: history of type 1 or type 2 diabetes * part b: history of type 1 diabetes

Keywords: overweight obese fructose sirna hba1c insulin glucose
comparative study between tonometers

Conditions: Glaucoma Eye

Summary: comparative study between the goldmann flattening tonometer and the non-contact tonometer in patients of a reference ophthalmological hospital


Eligibility criteria:
inclusion criteria:pacients with glaucoma diagnosed - exclusion criteria:pacients without glaucoma diagnosed -